AstraZeneca
AZN
554 hedge funds and large institutions have $20.4B invested in AstraZeneca in 2019 Q3 according to their latest regulatory filings, with 63 funds opening new positions, 181 increasing their positions, 185 reducing their positions, and 52 closing their positions.
133% more funds holding in top 10
Funds holding in top 10: 3 → 7 (+4)
43% more call options, than puts
Call options by funds: $104M | Put options by funds: $72.7M
21% more first-time investments, than exits
New positions opened: 63 | Existing positions closed: 52
7% more capital invested
Capital invested by funds: $19B → $20.4B (+$1.42B)
1% more funds holding
Funds holding: 546 → 554 (+8)
0.09% less ownership
Funds ownership: 17.53% → 17.44% (-0.09%)
2% less repeat investments, than reductions
Existing positions increased: 181 | Existing positions reduced: 185
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$150M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$149M |
| 3 |
Jennison Associates
New York
|
+$90.9M |
| 4 |
Goldman Sachs
New York
|
+$68.6M |
| 5 |
Allianz Asset Management
Munich,
Germany
|
+$58.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$331M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$74.8M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$61.2M |
| 4 |
Renaissance Technologies
New York
|
-$54.4M |
| 5 |
EIP
Epoch Investment Partners
New York
|
-$43.2M |
AZN Hedge Fund Activity: Q3 2019 in Review
554 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q3 2019, worth a combined $20.4B — up 7.5% from $19B a quarter earlier.
Buyers outnumbered sellers: 63 funds opened new AZN positions and 52 closed out — a net gain of 11 holders — while 181 added to existing stakes and 185 trimmed.
The largest buyer was Invesco, adding an estimated $150M. The largest seller was Bank of America, cutting an estimated $331M.
- 554 institutional investors held AstraZeneca (AZN) as of Q3 2019, up from 546 in Q2 2019.
- Funds reported $20.4B of AstraZeneca stock for Q3 2019, up 7.5% quarter-over-quarter.
- 63 funds opened new AstraZeneca positions in Q3 2019 and 52 closed out, a net change of +11 holders.
- The largest AstraZeneca buyer in Q3 2019 was Invesco, an estimated $150M added.
- The largest AstraZeneca seller in Q3 2019 was Bank of America, an estimated $331M sold.
Based on aggregated 13F filings for Q3 2019.